Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Ascending Dose Study of Psilocybin in Healthy Volunteers
NCT07710027Phase 1Completed
- Sponsor
- Diamond Therapeutics
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in anxiety disorder and major depressive disorder (MDD) (11 arms), sponsored by Diamond Therapeutics. Primary endpoints: Clinical Safety Event Frequency at 1 week, Clinical Safety Event Severity at 1 week and 14 more. Started Oct 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07710027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710027.